Резистентная артериальная гипертония: новые возможности интервенционного лечения

Автор: Свешников А.В., Воробьев А.С.

Журнал: Вестник Национального медико-хирургического центра им. Н.И. Пирогова @vestnik-pirogov-center

Рубрика: Обзоры литературы

Статья в выпуске: 1 т.8, 2013 года.

Бесплатный доступ

Короткий адрес: https://sciup.org/140188145

IDR: 140188145

Список литературы Резистентная артериальная гипертония: новые возможности интервенционного лечения

Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease. 2001. Lancet 2008; 371: 1513-1518.
Veterans Administration Cooperative Study Group on Antihypertensive Agents, «Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg», Journal of the American Medical Association, 1967, Vol. 202, N. 11, P. 1028-1034.
Veterans Administration Cooperative Study Group on Antihypertensive Agents, «Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 90 through 114 mm Hg», Journal of the American Medical Association, 1970, Vol. 202, P. 1143-1152.
CDC. Vital signs: prevalence, treatment, and control of hypertension-United States, 1999-2002 and 2005-2008. MMWR. 2011; 60(4): 103-8.
Kotseva K, Wood D, De Backer G et al. EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121-137.
Mancia G, Pessina AC, Trimarco B, Grassi G. SILVIA (Studio Italiano Longitudinale sulla Valutazione della Ipertensione Arteriosa nel 2000) Study Group. Blood pressure control according to new guidelines targets in low-to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22: 2387-2396.
Mancia G, Volpe R, Boos S, Ilardi M, Giannattasio C. Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care. J Hypertens 2004; 22: 51-57.
Guido Grassi, Renata Cifkova, Stephane Laurent et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J (2011) 32 (2): 218-225.
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51: 1403-19.
Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002; 4: 393-404.
Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290: 199-206.
de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 898-902.
P. A. Sarafidis and G. L. Bakris, «Resistant hypertension. An overview of evaluation and treatment,» Journal of the American College of Cardiology, 2008, Vol. 52, N. 22, P. 1749-1757.
M. Moser and J. F. Setaro, «Resistant or difficult-to-control hypertension,» The New England Journal of Medicine, 2006, Vol. 355, N. 4, P. 385-392.
D. Wojciechowski, V. Papademetriou, C. Faselis, and R. Fletcher, «Evaluation and treatment of resistant or difficult to control hypertension,» Journal of Clinical Hypertension, 2008, Vol. 10, N. 11, P. 837-843.
Lloyd-Jones DM, Evans JC, Larson MG, O’Donnell CJ, Rocella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000; 36: 594-599.
L. Barajas, L. Liu, and K. Powers, «Anatomy of the renal innervation: intrarenal aspects and ganglia of origin», Canadian Journal of Physiology and Pharmacology, 1992, Vol. 70, N. 5, P. 735-749.
G. F. DiBona and U. C. Kopp, «Neural control of renal function», Physiological Reviews, 1997, Vol. 77, N. 1, P. 75-197.
U. C. Kopp and G. F. DiBona, «The neural control of renal function» in The Kidney: Physiology and Pathophysiology, G. Seldin and G. Giebisch, Eds., pp. 981-1006, Raven Press, New York, NY, USA, 3rd edition, 2006.
Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol, 2010; 15: 570-576.
L. Liu and L. Barajas, «The rat renal nerves during development,» Anatomy and Embryology, vol. 188, no. 4, pp. 345-361, 1993.
Esler M., Jennings G., Lambert G., Meredith I., Horne M., Eisenhofer G.; Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions, Physiol Rev 70 1990 963-985
Harris SH. Renal sympathectomy: its scope and limitations. Proc R Soc Med. 1935;28:1497-1510.
Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953; 152: 1501-1504.
Hoobler SW, Manning JT, Paine WG, et al. The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study. Circulation. 1951; 4: 173-183.
R. H. Smithwick, «Hypertensive vascular disease. Results of and indications for splanchnicectomy,» Journal of Chronic Diseases,1955, Vol. 1, N. 5, P. 477-496.
Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-4.
Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet, 2010; 376: 1903-1909.
H. Krum, N. Barman, M. Schlaich, P. Sobotka et al. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension. Hypertension. 2011; 57: 911-917.
http://www.symplifybptrial.com/.
Mahfoud F, Schlaich M, Kindermann I, et al.: Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-6.
Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012.
http://clinicaltrials.gov/ct2/show/NCT01366625.
http://clinicaltrials.gov/ct2/show/NCT01588795.
http://clinicaltrials.gov/ct2/show/NCT01538992.
http://clinicaltrials.gov/ct2/show/NCT01392196.
Warner HR. The frequency-dependent nature of blood pressure regulation by the carotid sinus studied with an electric analog. Circ Res. 1958; 6: 35-40.
Carlsten A, Folkow B, Grimby G, Hamberger CA, Thulesius O. Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. Acta Physiol Scand. 1958; 44: 138-45.
Schwartz SI, Griffith LS, Neistadt A, Hagfors N. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg. 1967; 114: 5-15.
Bilgutay AM, Lillehei CW. Treatment of Hypertension with an Implantable Electronic Device. JAMA. 1965; 191: 649-53.
Bilgutay AM, Lillehei CW. Surgical treatment of hypertension with reference to baropacing. Am J Cardiol. 1966; 17: 663-7.
Scheffers IJ, Kroon AA, Schmidli J, et al.: Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. Journal of the American College of Cardiology 2010; 56: 1254-8.
Bisognano JD, Bakris G, Nadim MK et al.: Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58(7): 765-73.
Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012 Jul-Aug;6(4): 270-6.

Еще

Статья обзорная